The lack of effect of the SH-4-54 inhibitor on GBM10, in spite of presenting wildtype STAT3, suggests varied effectiveness of this inhibitor, and highlights the heterogeneity of responses that GBM patient-derived cell lines can exhibit after treatment. Here, STAT3 is linked to glioblastoma.